ABVC BioPharma Inc (NASDAQ: ABVC)’s stock price has increased by 7.42 compared to its previous closing price of 0.56. However, the company has seen a 15.99% increase in its stock price over the last five trading sessions. globenewswire.com reported 2024-12-11 that FREMONT, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) — ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company advancing therapeutic solutions in ophthalmology, CNS (central nervous system), and oncology/hematology, announced the receipt of a $200,000 cash payment from OncoX BioPharma Inc. (“OncoX”) as part of its strategic licensing agreement for certain oncology-related products; this payment marks the first installment of $5 million in potential licensing fees from OncoX. With this payment, the total accumulated cash payment ABVC has received from its three strategic partners for licensing various ABVC products is $546,000. ABVC and its subsidiaries BioLite Inc. and Rgene Corporation are each eligible to receive up to 10M OncoX shares, $5M cash payment, and royalties up to $50M after the product launches.1
Is It Worth Investing in ABVC BioPharma Inc (NASDAQ: ABVC) Right Now?
Moreover, the 36-month beta value for ABVC is 0.74. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ABVC is 11.13M and currently, short sellers hold a 5.64% of that float. On December 27, 2024, ABVC’s average trading volume was 255.67K shares.
ABVC’s Market Performance
ABVC’s stock has seen a 15.99% increase for the week, with a 18.68% rise in the past month and a -12.63% fall in the past quarter. The volatility ratio for the week is 10.19%, and the volatility levels for the past 30 days are at 8.76% for ABVC BioPharma Inc The simple moving average for the past 20 days is 15.33% for ABVC’s stock, with a -24.04% simple moving average for the past 200 days.
ABVC Trading at 8.01% from the 50-Day Moving Average
After a stumble in the market that brought ABVC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.49% of loss for the given period.
Volatility was left at 8.76%, however, over the last 30 days, the volatility rate increased by 10.19%, as shares surge +20.07% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.73% upper at present.
During the last 5 trading sessions, ABVC rose by +18.33%, which changed the moving average for the period of 200-days by -50.20% in comparison to the 20-day moving average, which settled at $0.5215. In addition, ABVC BioPharma Inc saw -48.23% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ABVC
Current profitability levels for the company are sitting at:
- -12.42 for the present operating margin
- 0.71 for the gross margin
The net margin for ABVC BioPharma Inc stands at -16.17. The total capital return value is set at -0.78. Equity return is now at value -90.91, with -51.96 for asset returns.
Based on ABVC BioPharma Inc (ABVC), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -1.05. The debt to equity ratio resting at 0.22. The interest coverage ratio of the stock is -2.79.
Currently, EBITDA for the company is -8.13 million with net debt to EBITDA at -0.34. When we switch over and look at the enterprise to sales, we see a ratio of 19.57. The receivables turnover for the company is 42.51for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.34.
Conclusion
To wrap up, the performance of ABVC BioPharma Inc (ABVC) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
